{"nct_id":"NCT05259839","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","status_verified_date":"2025-08","start_date":"2022-10-20","start_date_type":"ACTUAL","primary_completion_date":"2033-09","primary_completion_date_type":"ESTIMATED","completion_date":"2033-09","completion_date_type":"ESTIMATED","phases":["PHASE1"],"tickers":["ABBV"]}